Join
Live feed
·
PRReleasevia Quantisnow
Alkermes plc logo

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

ByQuantisnow·Wall Street's wire, on your screen.
ALKS· Alkermes plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALKS (Alkermes plc) and more on Quantisnow.